chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Patient had erythematous area at left lateral deltoid where Tdap was administered. He denied any fever chills cold or flu symptoms. Patients stated it wasn't sore but did itch. There was also a row of small papules under left breast chest wall. There were no pustule or any true vesicles and the area was non tender. This was all observed on 7/10/2020 two days after immunization was administered.
The recipient is 16yo and received Moderna, which is only approved for 18 and over.
Measles like rash on face the morning after both doses; This is a spontaneous report from a contactable consumer, the patient. A 28-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration on 28Mar2021 (at the age of 28-years-old) as a single dose for COVID-19 immunisation and received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the right arm on 18Apr2021 at 12:45 (at the age of 28-years-old) as a single dose for COVID-19 immunisation. Other medical history not reported. Prior to the vaccination, the patient was not diagnosed with COVID-19. Concomitant medications were not reported. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 29Mar2021 at 08:00, the patient experienced measles like rash on face the morning after both doses. The event did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the event. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event measles like rash on face was recovering at the time of this report.   No follow-up attempts are needed; information about lot/batch number cannot be obtained.
COVID vaccine breakthrough case. Vaccinated 3/23/21 EN6202, 4/13/21 ER8732, and boosted 1/5/22 FJ8757
This spontaneous report was received from a physician via company representatives referring to a patient of unknown age and gender (encounter key #80752). The patient's concurrent conditions and medical history were not provided. On 16-OCT-2014, the patient was vaccinated with an improperly stored dose of PNEUMOVAX 0.5 mL (VIs 10 SDV) (Lot # K007822, expiration date 15-AUG-2015) single dose, route and anatomical location were not provided. There was no concomitant medication provided. No adverse effects were reported. On an unknown date, PNEUMOVAX had a temperature excursion for 384 hours, the lowest recorded temperature was 20F (-6.667 Celsius). The vaccine status was reported as "in excursion", the storage criteria and the vaccine excursion were reported as "Refrigerator (R)". There was no product quality complaint involved. This is one of several cases received from the same reporter. Additional information has been requested.
sudden itchiness of injection site with raised red hives. eventually growing to one large lump. Talked to immediate supervisor. Went to ED to show Dr. took zyrtek.
reconstituted the menveo powder (men A) with sterile water; reconstituted the menveo powder (men A) with sterile water; This case was reported by a other health professional via call center representative and described the occurrence of wrong solution used in drug reconstitution in a 13-year-old male patient who received Men ACWY-CRM NVS (Menveo) (batch number AMVA419A, expiry date October 2021) for prophylaxis.   On an unknown date, the patient received Menveo. On an unknown date, unknown after receiving Menveo, the patient experienced wrong solution used in drug reconstitution and inappropriate dose of vaccine administered. On an unknown date, the outcome of the wrong solution used in drug reconstitution and inappropriate dose of vaccine administered were unknown.  Additional details were reported as follows: The age at vaccination was not reported. The reporter's coworker reconstituted the Menveo powder (Men A) with sterile water and not the diluent provided, which led to wrong solution used in drug reconstitution and inappropriate dose of vaccine administered. The reporter wanted to know if the patient needs to come back for revaccination. The reporter consented to follow up.
Vial was opened at 08:15 AM, remained refrigerated until last dose was given at 5:45 PM. This is the only dose given outside of the 6 hour time frame.
pt recvd vax & exp jt pain & swelling; pt exp same symptoms as well as rash;
After 24 hrs of vaccination , patient started feeling dizzy upon getting up from bed and has daily frontal headaches with eye twitching
pt recv vax 10JAN97 @ approx 830AM devel hives,swelling on face on Saturday @ approx 1030PM; swelling & hives cont;
07:50 Client noiticed metalic taste in her mouth, tingling of her tongue and lower lip.      07:58   154/82 98%pso2   heart rate 81 said thought she should mention it once tingling of her tongue started.  No signs of distress. 08:09 tingling gone just feels a sensation on her tongue does not want to be seen in ER or continued to be monitored.  States she feels safe to go.  Informed to seek medical attention for further problems.  Also informed to notify her MD of the event so he can advise for 2nd covid vaccine. 140/82  pso298% heart rate 77.  No signs of distress.
The pediatric dose was given instead of the adult dose of the vaccine. No harm to patient no reaction. The patient was instructed to return for adult dose of the vaccine.
This spontaneous report was received from a physician via a company representative concerning to a patient of unknown age and gender. There was no information about the patient's concurrent conditions, medical history or concomitant medication. On an unspecified date, the patient was vaccinated with subcutaneous ZOSTAVAX (strength, dose, lot number and expiration date were not reported) to prevent shingles.  On an unknown date, after the patient received ZOSTAVAX, the patient developed shingles. The outcome of the event shingles was unknown and the causal relationship between the event and the ZOSTAVAX were not reported. Additional information is not expected because there was no consent to contact physician.
1st dose administered 9/10/22 at 1pm. N 9/11/22 at 3am, patient developed tachycardia with pulse noted to be 191. Patient complained of dizziness and lightheadedness and was tranferred to the ER for evaluation and was admitted for further evaluation.
No other AE/PQC reported; PROQUAD was inadvertently given to an 18 year old patient; This spontaneous report was received from a medical assistant referring to an 18-year-old patient. The patient's concurrent conditions, medical history, and concomitant medications were not reported.  On 11-AUG-2021, the patient was inadvertently vaccinated with measles, mumps, rubella, and varicella (oka-merck) virus vaccine live(PROQUAD) (lot # T032145 with an expiration date on 20-MAR-2022) for prophylaxis  (strength, dose, frequency, route of administration, lot #, and expiration date were not reported) at the age of 18 years old (product administered to patient of inappropriate age).  No adverse events were reported.
Myalgia, Fever, ErythemaMultiform, Injection site pain and swelling, fatigue and insomnia Narrative:
his hole hand became red and swollen; his hole hand became red/he felt redness around the injection site; This case was reported by a pharmacist via call center representative and described the occurrence of extensive swelling of vaccinated limb in a 69-year-old male patient who received Herpes zoster (Shingrix) (batch number 4RF5J, expiry date 25th April 2022) for prophylaxis.   On 29th February 2020, the patient received the 2nd dose of Shingrix. On an unknown date, less than a week after receiving Shingrix, the patient experienced extensive swelling of vaccinated limb and erythema of extremities. On an unknown date, the outcome of the extensive swelling of vaccinated limb and erythema of extremities were unknown.   It was unknown if the reporter considered the extensive swelling of vaccinated limb and erythema of extremities to be related to Shingrix.  Additional details were provided as follows: The reporter reported a patient developed adverse reactions following the dose of Shingrix received on an unknown arm. Whole hand became red and swollen (extensive swelling of vaccinated limb), and also felt redness around the injection site. The reporter provided consent to be contacted for the follow-up of this case.
Woke up 3 am Day 1 with cough, fever, severe lower back pain, experienced bad diarrhea, mild cough, sever chills,  muscular aches, very sore in both arms in the injection areas, which didn't make sense, and a huge water blister formed at the new injection site that burst with yellow liquid oozing out, 24 hours after injection. Day 2, nocturnal fever, lower back pain, nausea.
This spontaneous report was received from a nurse refers to a patient of unknown age. The patient's pertinent medical history, drug reactions/allergies and concomitant medications were not reported. On 02-AUG-2016, the patient was inadvertently administered PNEUMOVAX 23 lot # L001311, which expired on 06-JUL-2016. No adverse effects reported. Additional information has been requested.
Patient had immediate knot come up and arm became inflamed and swollen. Asked patient if she was having any other symptoms and she reported dizziness and thirsty and almost passed out.
PIns and Needles for several hours on and off. Went away after 8 hours
HEADACHE; This spontaneous report received from a patient via a company representative concerned a male of unspecified age. The patient's weight, height, and medical history were not reported.  The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported,) dose was not reported, administered on MAR-2021 for prophylactic vaccination. The batch number was not reported. The Company is unable to perform follow-up to request batch/lot numbers.  No concomitant medications were reported.  On MAR-2021, the subject experienced headache. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The outcome of headache was not reported. This report was non-serious.
no additional AE reported; Nurse reported GARDASIL 9 administered to patient after temperature excursion; This spontaneous report was received from a nurse referring to a patient of unknown age. The patient's pertinent medical history, concurrent conditions, drug reactions/allergies and concomitant medications were not provided.     On 23-JUL-2020, after a temperature excursion, the patient was vaccinated with hpv rl1 6 11 16 18 31 33 45 52 58 vlp vaccine (yeast) (GARDASIL 9) 0.5 ml, for prophylaxis, non-valid lot #163741, expiration date reported on 16-FEB-2022. Vaccine was stored at a temperature of 8.83°C, during a time frame of 20 hours. There was no additional adverse experiences neither previous temperature excursion reported. The call was because of a data logger.
side effects; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION COMPLICATION (side effects) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced VACCINATION COMPLICATION (side effects). At the time of the report, VACCINATION COMPLICATION (side effects) outcome was unknown.            No concomitant medications were provided. No treatment medications were provided.
This spontaneous report has been received from an administrator referring to a 18 month old patient (no gender reported). No information was provided regarding the patient's medical history, concurrent conditions, drug, allergy history or concomitant medications. On 22-FEB-2018, the patient was vaccinated with a dose of PROQUAD, lot# N022954, expiration date 19-FEB-2019 (strength, dose, frequency and route of administration were not provided) for prophylaxis. The reporter stated that on 29-MAY-2018, the patient received another dose of PROQUAD lot # N034561, expiration date 03-JUN-2019 (strength, dose, frequency and route of administration were not provided) for prophylaxis. Other suspect therapies included sterile diluent (MRK) (dose, frequency, route of administration, lot# and expiration date were not provided) for prophylaxis. No adverse events were provided.
Headache, Myalgia, Arthralgia, Fever, CoughWheeze, Extreme Fatigue, Chills, Body Aches, Fever 101.1; decreased 02 sats during worst of the chills last night- had to put O2 back on. Injection site soreness. Everything started about 0200. Was critically ill with COVID pneumonia in Nov/Dec. Have been muc Narrative:
Day 2 after vaccination I experienced severe headache, dizziness on standing, and stroke like movement in my right leg being unable to advance it normally when walking and my right foot turning so that I stood on the outside border of my foot. After sitting down I experienced visual disturbance in my right eye of blurred vision and corona of bright lines that zigzagged. These symptoms slowly resolved over the next hour, but left with extreme fatigue.
Pain in upper arm, pain has increased and has effected range of motion, especially when getting dressed.
Approximately 1 to2 hours post 2 hives on top of each foot, treated with benadryl topical. Relief  5 hours post- chills, restlessness, and body aches, treated with Tylenol no improvement, clonazepam taken to help sleep, slept 3 hours. 9 hours post- low grade fever, restless, body aches, treated with Tylenol no improvement. 14 hours post- swelling of both lips and around the mouth, body aches, tried Tylenol again still no improvement.  20 hours post- lip and around the mouth still swollen still body aches low grade fever with PCP approval took benadryl and ibuprofen body aches improved fell asleep 26 hours post- body aches mild, no fever, lips and around mouth decreased a small amount, ibuprofen  helped with body aches again. 27 hours 30minutes post- swelling still present took benadryl again and went to bed. Slept through the night. 37 hours post- feeling much better, very small amount of swelling with lips and around mouth, slight injection site soreness
received vaccine past published expiry; This spontaneous case was reported by an other health care professional and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (received vaccine past published expiry) in a  patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 050e21a) for COVID-19 vaccination.     No Medical History information was reported.    On 20-Oct-2021, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 20-Oct-2021, the patient experienced EXPIRED PRODUCT ADMINISTERED (received vaccine past published expiry). On 20-Oct-2021, EXPIRED PRODUCT ADMINISTERED (received vaccine past published expiry) had resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant medication information was provided.  No treatment medication were provided.  Reporter wanted to know if the lot number 050e21a was or would be extended.  No adverse reactions reported.   This case was linked to MOD-2021-403096, MOD-2021-403113 (Patient Link).
Pt came to ER with difficulty breathing, was recently covid positive.  Lives in a healthcare facility with other positive patients.
Within a minute of getting this vaccine, my teeth then gums started to tingle then go numb.  Face felt flush.  Within 3 minutes my mouth got extremely dry, like cotton.  It became very hard to swallow.  It felt like a ping pong ball was in my throat as I drove home.  Breathing became difficult.   Difficulty swelling lasted about 60-90 min.  Within about an hour it started to subside.  I sipped water, did not think I could make it to the local ER.  After two hours, it seemed the event was over.  Then around 5pm that evening, I had similar symptoms again, but less severe, which lasted about 20 minutes.  Very scary.  My arm at injection site  is also very sore,.  I had body aches similar to flu that same evening which continued to the following day. Still  taking place.  I was warned that could be a side effect of the vaccination.
This spontaneous report as received from a physician, via a company representative, refers to a 80 year old patient. On an unknown date, the patient was vaccinated with ZOSTAVAX (lot number and expiry date not provided). On an unknown date, the patient developed an abscess on the arm that was used to administer ZOSTAVAX (hospitalization). The patient required surgery on the affected arm (hospitalization) and was hospitalized in an unspecified hospital on an unspecified date. The outcome of developed an abscess on the arm that was used to administer ZOSTAVAX and surgery on the affected arm was unknown. The physician has had two follow-up appointments with the patient on unspecified dates and stated that the patient was "ok". The reporter did not assess the relationship between the events and ZOSTAVAX. Additional information has been requested.
Subsequent to receiving the third dose of Lymerix, the pt experienced left arm pain and pain in her left third finger. As of 06/28/2000 the outcome of the events is unknown.
Information has been received from a physician referring to a 6 years old male patient. Information about pertinent medical history, concurrent conditions, concomitant medication and drug reactions/allergies was not provided. On an unknown date, the patient received 2 doses of M-M-R II (lot number, expiration date, dose, frequency, route unspecified) for prophylaxis. This patient was not administered a third dose of M-M-R II as he had Crohn's disease. It was undetermined if the Crohn's disease had manifested before or after receiving the vaccine. Blood work was done on the patient and tested negative for Mumps (Mumps antibody test negative). It was unknown if the treatment was given for the events. Outcome of the events was unknown. Causality assessment was not reported. Upon internal review, Crohn's disease was determined to be medically significant. This is one of several reports received from the same reporter.; Sender's Comments: US-009507513-1906USA000289: Original Case : 1906USA000133.
Itching at injection site that began 6 days after receiving the vaccine.  Redness at the injection site and extending 2 inches beginning 7 days after receiving the vaccine.  Ongoing as of the date of this report.
I had put on compression sleeve for both my knees on Saturday. Sunday my left knee was bruised in two places where the sleeve was at.; This is a spontaneous report from a contactable consumer (patient). This consumer reported that a 59-year-old male patient received first dose of bnt162b2 (Pfizer-Biontech COVID-19 Vaccine, solution for injection, Lot number: EN6201), via an unspecified route of administration in right arm on 12Mar2021 at 09:00 (at the age of 59-year-old) as single dose for COVID-19 immunisation. It was other facility type vaccine. The patient's medical history was hypertension and allergic to Penicillin. Concomitant medications in two weeks included Losartan and Tamsulosin from an unknown date. No other vaccine in four weeks. On 13Mar2021 at 09:00, the patient had put on compression sleeve for both my knees on Saturday. Sunday my left knee was bruised in two places where the sleeve was at. No covid prior vaccination. Post vaccination no covid tested was performed. No treatment was received for adverse event. The outcome of the adverse event was unknown.  No follow-up attempts are possible. No further information is expected.
I suffered a stroke 24 hours after receiving vaccine; This is a spontaneous report from a contactable consumer (patient). A 69-year-old male patient received the first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, Lot number was not reported), via an unspecified route of administration, administered in Left arm on 20Feb2021 (at the age of 69-year-old) at 11:15 AM at single dose for covid-19 immunisation. The patient medical history and concomitant medications were not reported. The patient had no known allergies. The patient had no Covid prior vaccination and patient had COVID tested post vaccination. The patient suffered a stroke about 24 hours after receiving vaccine on 21Feb2021 at 10:30. The event result in hospitalization for 2 days in Feb2021 and considered as life threatening illness (immediate risk of death from the event).  The patient underwent lab tests and procedures which included Nasal swab was negative on 23Feb2021. Treatment included blood thinner. The outcome of the event was not recovered.  Information on lot number/batch number has been requested.
In early January (approximately 01/10/2022) I developed the same rash as I developed after the second dose. It was red, itchy, rough in texture, darker in color and extended from mid forearm to shoulder area on both arms. I went to the dermatologist and they gave me a cream (Clobetasol) which alleviated the symptoms in about 3-4 days.
This spontaneous report was received from a pharmacist via company representative and refers to a 77 year old female patient. The patient's concurrent conditions, medical history and concomitant therapies were not reported. The patient was given PREVENAR a "year ago", in approximately 2015. On an unspecified date in approximately October 2016 (reported as "within the last week"), the patient was vaccinated with PNEUMOVAX 23 (dose, lot # and expiration date were not reported) intramuscularly. A couple hours later, the patient developed redness and swelling in the arm she got vaccine in. A day later, the patient became disoriented and fell. She hit her head and broke her nose. The patient went back the pharmacy "72 hours later" and she still had swelling. The patient used BENADRYL and a cold compress to treat the swelling. The pharmacist did not specify if the patient sought medical for her broken nose. The patient outcome was not reported. Action taken was not applicable. The causality between the events and PNEUMOVAX 23 was not provided. Upon internal review the event of facial bones fracture was considered to be medically significant. Additional information has been requested.
Site: Pain at Injection Site-Mild, Site: Redness at Injection Site-Mild, Site: Swelling at Injection Site-Mild, Additional Details: round red circular rash, left deltoid, patient said warm to touch,pain at injection site
My radial nerve was hit during the injection and I have had little to no feeling in my left pinky finger since receiving the shot.
When lifting my arm it is painful. While sleeping if I move it is very painful. It is still hurting after 5 1/2 weeks after shot.